Peter Cimermancic leads Pathology Machine Learning Team at Verily Life Sciences. Dr. Cimermancic was awarded the Howard Hughes Medical Institute Predoctoral Fellowship at University of California, San Francisco where he received his PhD in Biomedical Informatics in 2014.
AI and Data Science Showcase:
Verily Life Sciences
Verily lives at the intersection of technology, data science and healthcare. Our mission is to make the world's health data useful so that people enjoy healthier lives.
Tissue-Sparing Image-Based Diagnostics Using Machine Learning
The current tissue requirements for diagnosis and treatment-guiding biomarker testing in lung adenocarcinoma may exhaust an entire tumor sample. With many additional biomarker-guided therapies currently in development, this biomarker testing paradigm is unsustainable. Our work explores how tissue-based biomarker testing may be replaced by standard tissue imaging and machine learning.
The PMWC 2020 AI Company Showcase will provide a 15-minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.